The webinar will feature presentations by Key Opinion Leaders (KOLs) Daniel H. Ahn, D.O. (Mayo Clinic Arizona) and Manish R. Sharma, M.D. (START Midwest), who will discuss the current treatment landscape and unmet medical need in KRAS-mutated metastatic colorectal cancer (mCRC), as well as the ongoing Phase 1b/2 clinical trial and observations from the Expanded Access Program evaluating onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated mCRC.
During the webinar, Cardiff's CEO, Mark Erlander, Ph.D., will give a corporate update and outlook for the year. Dr. Erlander and Drs. Sharma and Ahn, will be available to answer questions following the conclusion of the formal presentations.